Artificial platelet lysate, methods for preparation and uses thereof

In vitro artificial platelets combined with plasma-derived proteins provide a superior cell culture supplement, addressing variability and safety issues of donor-derived lysates, enhancing cell growth and standardization in cell culture.

WO2026234149A1PCT designated stage Publication Date: 2026-11-12PL BIOSCI GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063203
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing cell culture media rely on animal-derived supplements like fetal bovine serum (FBS) that pose immune reaction and pathogen transmission risks, and donor-derived human platelet lysate (HPL) suffers from variability and supply issues, limiting their widespread adoption in cell culture and therapy.

Method used

A lysate is derived from in vitro artificial platelets combined with plasma-derived proteins, creating a synergistic effect that enhances cell growth, particularly for mesenchymal stem cells, and is produced in a standardized, xeno-free, and clinically-grade form.

Benefits of technology

The artificial platelet lysate composition outperforms donor-derived preparations, offering improved consistency, standardization, and higher cell growth-promoting effects, while eliminating immune reaction and pathogen transmission risks.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000032_0001
    Figure IMGF000032_0001
  • Figure IMGF000032_0002
    Figure IMGF000032_0002
  • Figure IMGF000043_0001
    Figure IMGF000043_0001
Patent Text Reader

Abstract

The present invention pertains to an artificial platelet lysate composition, a protein composition and an artificial platelets composition, based on artificial platelets (or "artificial platelets"). The compositions of the present invention are suitable for cell culture, cell therapy, gene therapy, a tissue-engineered product or an advanced therapy medicinal product (ATMP), in particular cell culture of stem cells and the like. The compositions of the invention preferably comprises artificial platelets or their lysate, supplemented with one or more protein sources exogenous to platelets, most preferably human plasma which may synergize with the bioactive effects of the artificial platelet lysate. The compositions of the invention may provide for an alternative, or even improvement, over known donor-derived platelet lysates.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] P37368PC00 / MCR - 1 -

[0002] Artificial platelet lysate, methods for preparation and uses thereof

[0003] TECHNICAL FIELD

[0004] The present invention pertains to platelet lysate composition based on artificial platelets (or “induced platelets”). The compositions of the present invention are suitable for cell culture, cell therapy, gene therapy, a tissue-engineered product or an advanced therapy medicinal product (ATMP), and the like.

[0005] BACKGROUND OF THE INVENTION

[0006] Ex vivo or in vitro cell culture typically makes use of basic growth media supplemented with further components that support cell attachment, proliferation, and survival. Fetal bovine serum (FBS) has traditionally been used as cell culture supplement due to its high content of growth-promoting factors, foremost growth factors, hormones and nutrients. Additionally, the reduced antibody content and limited presence of growth-inhibitory elements in FBS further enhance its usefulness in cell culture.

[0007] However, as a limitation, FBS is associated with concerns over unwanted immune reactions, pathogen transmission, and animal welfare. Moreover, use of animal-derived products hampers transitions from lab studies to approved treatments, especially under strict regulatory frameworks like the European Medicines Agency’s (EMA) guidelines for Advanced Therapy Medicinal Products (ATMPs). As a consequence, there has been an increasing regulatory and ethical scrutiny towards use of FBS or other animal-derived products in cell culture.

[0008] Although chemically-defined, xeno-free media have been developed as alternatives to FBS, they typically show suboptimal support in growth or differentiation of many cell types, supposedly due their limited growth factor complexity. Moreover, the need of high-purity reagents and custom formulations for chemically-defined media is associated with higher costs.

[0009] In view of the aforementioned, the attention has shifted toward human-derived alternatives like human donor-derived platelet lysate (HPL) as supplement used to support cell growth during in vitro cell culture and expansion, particularly in the development of cell-based therapies (Palombella et al. Stem Cell Res Ther. 2022 Apr 4;13(1):142). HPL is typically derived from outdated human platelet concentrates, which are lysed (e.g. by freeze-thawing) to release their growth-promoting factors (e.g. growth factors like PDGF, TGF-p, EGF, VEGF, and IGF- 1 ). Since HPL contains clotting factors like fibrinogen, anticoagulants are usuallyP37368PC00 / MCR - 2 -

[0010] added and / or a fibrinogen-depletion step is performed. Because HPL is sourced from human blood, it generally presents fewer risks related to immune reactions or pathogen transmission compared to animal-derived supplements like FBS. In primary cell culture applications, HPL may even show advantages over FBS or chemically defined media, especially in enhancing the proliferation and functionality of mesenchymal stem cells (MSCs). These benefits include faster cell doubling times, improved expansion rates, and better maintenance of immunological and differentiation properties. In addition to its use as cell culture supplement and expansion of cells for therapeutic applications, HPL is being investigated for use in regenerative medicine to enhance tissue regeneration by providing growth signals (e.g. as bioactive component in a biomaterial or scaffold).

[0011] However, relying on donor-sourced platelets for the production of HPL presents several limitations. A first limitation when using platelets from diverse donors is the inevitable variability in HPL quality, which can depend on e.g. donor age, gender, and health status. The resulting differences in individual blood composition furthermore contribute to inconsistencies between batches, making it difficult to standardize the product for reproducible results in cell culture or cell therapy manufacturing. A second limitation is that production of HPL relies on a supply of high-quality donor-sourced platelets from selected authorized facilities permitted to collect blood, but which leads to unpredictable supply or even supply shortages. Overall, this limits the widespread adoption of HPL in cell culture.

[0012] The present invention aims to provide formulations with bioactivity in supporting cell growth and function, hence suitable as supplement in cell culture media, but which is xeno-free and which does not rely on donor-derived platelets. Overall, the invention aims to provide for an improved supplement for research / therapeutic cell culture or even for supporting in vivo tissue growth.P37368PC00 / MCR - 3 -

[0013] SUMMARY OF THE INVENTION

[0014] The aim of the invention is achieved by obtaining a lysate from in vitro artificial platelets (or “induced” platelets) and combining the lysate with further protein sources which are exogeneous to the platelets, more preferably plasma or plasma-derived proteins, most preferably human plasma.

[0015] It was found that the lysate obtained from in vitro artificial platelets by itself had no cell growth-promoting effects. Even more so, the cells showed no long-term survival in the lysate obtained from the in vitro artificial platelets. However, in combination with plasma-derived proteins, a synergistic cell growth-promoting effect was surprisingly observed in promoting cell growth. The artificial platelet lysate composition thus obtained even outperformed that of donor-derived high-protein human platelet lysate preparations.

[0016] The addition of plasma-derived proteins to donor-derived platelet lysate did not further enhance the cell growth-promoting effect. Moreover, alternative protein sources such as serum replacements (e.g. CELLstart) achieved only low cell growth rates in combination with artificial platelet lysate. Thus, this collectively points towards a synergistic interaction between specifically artificial platelet-derived factors and plasma-derived factors in stimulating cell growth.

[0017] Without being bound by theory, the present inventors consider that artificial platelets, such as those derived from induced pluripotent stem cells (iPSCs), may produce different compositions of growth factors as compared to donor-derived platelets. For example, insulinlike growth factor-1 (IGF-1) is generally considered as one of the key cell growth-promoting factors in donor-derived human platelet lysate, however IGF-1 appears not / hardly produced by iPSC-derived platelets nor present in the artificial platelet lysate compositions of the disclosure. Furthermore, artificial platelet lysate compositions lack interference from immune cell contributions (e.g. immune cell-derived cytokines). In addition or alternatively artificial platelets may produce overall lower levels of one or more growth factors, thus benefiting from supplementation with further protein sources.

[0018] It was found that the cell growth-promoting effects of artificial platelet lysate in combination with plasma proteins could be even further increased by adding further co-factors, including but not limited to anticoagulants which can have additional cell growth-promoting effects (e.g. heparin, dextran) or activating factors for platelets (e.g. thrombin, platelet-activating factor). The enhanced activation of the artificial platelets and the release of the growth factors in theP37368PC00 / MCR - 4 -

[0019] lysate, in conjunction with the supplemented proteins, may lead to higher performance rates of such lysates.

[0020] The present inventors found that the cell growth-promoting effects were highest if the relative amounts of artificial platelet-derived factors and exogeneous protein source are appropriately chosen. Hence, the present invention includes also the selection of relative amounts of artificial platelet-derived factors and exogeneous protein source in the artificial platelet lysate compositions disclosed herein.

[0021] Furthermore, the present inventors found that the lysate compositions of the invention may provide for growth factor compositions which are particularly favourable for mesenchymal stem cell (MSC) survival and growth. Hence, the present invention includes also the selection of cell types showing high responses to the artificial platelet lysate compositions disclosed herein, i.e. most preferably stem cells such as MSCs.

[0022] Moreover, the present inventors found particularly high cell growth-promoting effects for lysate compositions obtained from artificial platelets obtained from iPSC, e.g. as described in W02024076030A1.

[0023] Advantageously, compared to donor-derived platelet lysates, lysates derived from artificial platelets lead to improved standardization and consistency, and moreover offer a theoretically infinite source of artificial platelets. Moreover, the lysates of the present invention are xeno-free and can be produced at a clinical-grade. The compositions of the invention may provide not only for an alternative, but even an improvement, over known donor-derived platelet lysates currently used in cell culture.

[0024] In an aspect, the present invention pertains to method of producing an artificial platelet (or “induced” platelet) lysate composition suitable as cell culture supplement, the method comprising the steps of:

[0025] a) providing artificial platelets, preferably induced pluripotent stem cell (iPSC)-derived artificial platelets;

[0026] b) lysing at least part of the artificial platelets to provide an artificial platelet lysate, preferably an iPSC-derived artificial platelet lysate;

[0027] c) combining the artificial platelet lysate with plasma, preferably in relative amounts further described herein, more preferably in relative amounts such that

[0028] - the artificial platelet lysate provides platelet proteins in an amount of 0.01-5 mg / ml, calculated on the total of the artificial platelet lysate and the plasma; andP37368PC00 / MCR - 5 -

[0029] - the amount of plasma is 65-95% (v / v) and / or the plasma provides plasma proteins in an amount of 5-200 mg / ml, calculated on the total of the artificial platelet lysate and the plasma.

[0030] In an aspect, the present invention pertains to method of producing a medium composition suitable for cell culture, the method comprising the steps of:

[0031] a) providing artificial platelets, preferably iPSC-derived artificial platelets;

[0032] b) lysing at least part of the artificial platelets to provide an artificial platelet lysate, preferably an iPSC-derived artificial platelet lysate;

[0033] c) combining the artificial platelet lysate with plasma and basal medium to obtain the medium composition, preferably in relative amounts further described herein, more preferably in relative amounts such that

[0034] - the amount of artificial platelet lysate is 0.001-1 mg / ml, preferably 0.01-0.1 mg / ml, calculated on the medium composition;

[0035] - the amount of plasma is 1-20% (v / v), preferably 5-15% (v / v) and / or in an amount such that it provides plasma proteins in an amount of 0.5-50 mg / ml, preferably 1.0-10 mg / ml, calculated on the medium composition; and

[0036] - the amount of basal medium is 75-97% (v / v), calculated on the medium composition.

[0037] In an aspect, the present invention pertains to an artificial platelet lysate composition which is suitable as cell culture supplement, preferably an iPSC-derived artificial platelet lysate composition, wherein the artificial platelet lysate composition preferably comprises

[0038] - artificial platelet lysate providing platelet proteins, and

[0039] - one or more proteins exogenous to platelets, preferably plasma, more preferably human plasma.

[0040] In an aspect, the present invention pertains to a protein composition, preferably a medium composition, suitable as cell culture medium, wherein the protein composition preferably comprises

[0041] - medium (e.g. basal medium),

[0042] - artificial platelet lysate providing platelet proteins, and

[0043] - one or more proteins exogenous to platelets.

[0044] In an aspect, the present invention pertains to a method of producing the protein composition (e.g. medium composition) as disclosed herein.

[0045] In an aspect, the present invention pertains to an artificial platelet composition which is suitable for the preparation of a ready-to-use cell culture medium (e.g. protein composition as disclosed herein). Accordingly, the artificial platelet composition forms a starting material for aP37368PC00 / MCR - 6 -

[0046] platelet lysate-based cell culture medium. The artificial platelet composition (e.g. starting material) preferably comprises

[0047] - medium (e.g. basal medium),

[0048] - artificial platelets, and

[0049] - one or more proteins exogenous to platelets, preferably plasma, more preferably human plasma.

[0050] In an aspect, the present invention pertains to a method for producing the artificial platelet composition as disclosed herein.

[0051] In an aspect, the present invention pertains to a kit-of parts suitable for the preparation of the artificial platelet composition (e.g. starting material) or the protein composition (e.g. cell culture medium) disclosed herein, the kit-of-parts preferably comprising

[0052] - medium (e.g. basal medium),

[0053] - artificial platelets (e.g. in a liquid suspension),

[0054] - one or more proteins exogenous to platelets, preferably plasma, more preferably human plasma.

[0055] In an aspect, the present invention pertains to a method for producing an artificial platelet composition (e.g. starting material) using the kit-of-parts as disclosed herein.

[0056] In an aspect, the present invention pertains to use of the artificial platelet lysate composition (e.g. cell culture supplement), the protein composition (e.g. medium composition), the artificial platelet composition or the kit-of-parts as disclosed herein, preferably in one or more of cell culture, cell therapy, gene therapy, a tissue-engineered product or an advanced therapy medicinal product (ATMP).

[0057] In an aspect, the present disclosure pertains to a method of culturing cells.P37368PC00 / MCR - 7 -

[0058] DETAILLED DESCRIPTION OF THE INVENTION

[0059] Artificial platelet lysate composition and method of production thereof

[0060] In embodiments, the present invention pertains to an artificial platelet lysate composition suitable as cell culture supplement, the artificial platelet lysate composition comprising - artificial platelet lysate providing platelet proteins, and

[0061] - preferably one or more proteins exogenous to platelets.

[0062] The artificial platelet lysate composition as disclosed herein is preferably an artificial platelet lysate supplemented with one or more proteins exogenous to platelets, preferably one or more plasma proteins, more preferably plasma, even more preferably human plasma.

[0063] Artificial platelet lysate

[0064] The term “artificial platelet” in the context of the present invention means a platelet produced in vitro or ex vivo from a megakaryocyte or from a precursor cell of a megakaryocyte.

[0065] According, the term “artificial platelet” in the context of the present invention encompasses a platelet from a megakaryocyte which is obtained by in v / tro-induced differentiation of a progenitor cell to the megakaryocyte lineage. The progenitor cell to the megakaryocyte lineage may be, among others, an adult stem cell, an embryonic stem cell or an immortalized megakaryocyte progenitor cell line. The progenitor cell to the megakaryocyte lineage preferably is one or more of a hematopoietic stem cell (HSC), a multipotent progenitor (MPP), a common myeloid progenitor (CMP), a megakaryocyte-erythroid progenitor (MEP), a megakaryocyte progenitor (MkP). HSCs, MPPs, CMPs, MEPs, and MkPs are all progenitor stages that can ultimately lead to megakaryocytes. Through multiple steps, HSCs differentiate into multipotent MPPs, CMPs, MEPs, MkPs, and then megakaryocytes (MKs), which finally mature and produce functional platelets (Liu et al. Front Cell Dev Biol. 2021 Aug 12;9:713434). The HSCs, CMPs, MEPs and / or MkPs may be induced pluripotent stem cell (iPSC)-derived, meaning that the respective cell originates from iPSC which was differentiated into that cell in one or more differentiation steps. Varying methods of producing artificial platelets are known (e.g. described in Liu et al. Front Cell Dev Biol. 2021 Aug 12;9:713434, in particular Table 1 therein; Furniss etal. Blood. 2024 Nov 28;144(22):2283-2294, in particular Table 1 therein). The “artificial platelet” as disclosed herein is not limited by a certain production method. The “artificial platelet” in the context of the present invention is thus not directly obtained from a donor (e.g. human donor) and / or not directly isolated from donor (e.g. human donor) blood. The term “artificial platelet” can be used in the context of theP37368PC00 / MCR - 8 -

[0066] present invention to interchangeably refer to an “induced platelet”. The artificial platelet is preferably a human artificial platelet.

[0067] The “artificial platelet” in the context of the present invention encompasses engineered platelets, e.g. obtained from megakaryocytes or megakaryocyte precursors which have been artificially modified by transduction such as with a DNA-based vector or the like. To illustrate, EP4461301A1 describes a method for producing engineered platelets comprising the steps of:

[0068] - producing immortalized progenitors of megakaryocytes or immortalized CD34-expressing hematopoietic stem and progenitor cells (HSPC),

[0069] - transduction of a therapeutic sequence into said immortalized progenitors of megakaryocytes,

[0070] - differentiation of the transduced cells into megakaryocytes, and

[0071] - generation of artificial platelets.

[0072] In an embodiment, the progenitor cell to the megakaryocyte is a mesenchymal stem cell (MSC) and / or the artificial platelet is M SC-derived. For example, W02014208100A1 describes a method for producing megakaryocytes and / or platelets by culturing mesenchymal cells in a basal medium for mesenchymal cell culture that includes iron ions and an iron transporter, and collecting megakaryocytes and / or platelets from the culture.

[0073] In embodiments, the artificial platelet as disclosed herein is obtained or obtainable by the method of

[0074] - culturing megakaryocytes in the presence of thrombopoietin and / or stem cell factor, preferably thrombopoietin and stem cell factor, and allowing production of artificial platelets, - separating the artificial platelets from the megakaryocytes, preferably by one or more of centrifugation, density gradient separation and filtration, to obtain the artificial platelets.

[0075] In the megakaryocyte culture, the thrombopoietin is preferably present in a medium in a concentration of 50-150 ng / ml, preferably 80-120 ng / ml, more preferably 90-110 ng / ml. In the megakaryocyte culture, the SCF is preferably present in a medium in a concentration of 1-50 ng / ml, preferably 10-40 ng / ml, more preferably 20-30 ng / ml.

[0076] In a preferred embodiment, the megakaryocyte and / or artificial platelet as disclosed herein is iPSC-derived. In an embodiment, the artificial platelet is derived and / or obtainable from an in v / tro-differentiated megakaryocyte. In an embodiment, the artificial platelet is stem cell-derived, preferably human stem cell-derived and / or obtainable from the in vitro differentiation of a stem cell, preferably human stem cell. In an embodiment, the artificial platelet isP37368PC00 / MCR - 9 -

[0077] embryonic stem cell (ESC)-derived, preferably human-ESC derived. In an embodiment, the artificial platelet is HSC-derived, preferably human-HSC derived. In an embodiment, the artificial platelet is MPP-derived, preferably human-MPP derived. In an embodiment, the artificial platelet is CMP-derived, preferably human-CMP derived. In an embodiment, the artificial platelet is MEP-derived, preferably human-MEP derived. In an embodiment, the artificial platelet is MkP-derived, preferably human-MkP derived. In an embodiment, the artificial platelet is megakaryocyte-derived, preferably human megakaryocyte-derived.

[0078] In an embodiment, the artificial platelet is derived from an immortalized megakaryocyte progenitor cell line, preferably a human immortalized megakaryocyte progenitor cell line. The immortalized megakaryocyte progenitor cell line can be generated for instance from human ESC or iPSC as described before (e.g. Nakamura et al. Cell Stem Cell. 2014 Apr 3;14(4):535-48). EP4461301A1 also discloses methods of producing immortalized megakaryocytes, immortalized progenitors of megakaryocytes, or immortalized CD34-expressing HSPC.

[0079] In an embodiment, the artificial platelet as disclosed herein is iPSC-derived, preferably human iPSC-derived and / or obtainable from in vitro differentiation of an iPSC, preferably human iPSC. Advantageously, iPSC can expand limitlessly in vitro and have the potency to differentiate into essentially any kind of cell type, including hematopoietic lineages and ultimately into platelet-producing megakaryocytes. Methods of generating platelets from iPSC are already described, and include the stepwise differentiation from iPSCs to early hematopoietic progenitors, then to megakaryocytes and finally to platelets, by using different growth factor and cytokine combinations and culture media (e.g. Sugimoto et al. Cell Mol Life Sci. 2021 Jan 13; 78(7): 3385-3401; Liu et al. Front Cell Dev Biol. 2021 Aug 12;9:713434; W02024076030A1).

[0080] In a preferred embodiment, the iPSC-derived platelet is, or is obtained, as described in W02024076030A1, where the following embodiments are based on.

[0081] In embodiments, the artificial platelets are obtained by a method involving the steps:

[0082] Step 1) of culturing pluripotent stem cells, preferably iPSC,

[0083] Step 2) of obtaining a culture medium containing hematopoietic stem cells (HSCs),

[0084] Step 3) of differentiating the HSCs into megakaryocytes,

[0085] Step 4) of maturing the megakaryocytes and obtaining a culture medium comprising artificial platelets,

[0086] Step 5) of separating artificial platelets from the culture medium obtained in step 4).

[0087] Step 1:P37368PC00 / MCR - 10-

[0088] Preferably, the step of culturing the pluripotent stem cells (e.g. iPSC) comprises:

[0089] Step 1a) culturing the cells in medium containing a Glycogen Synthase Kinase 3 (GSK3) inhibitor, preferably followed by

[0090] Step 1b) culturing the cells in a medium containing vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), preferably followed by

[0091] Step 1c) culturing the cells in a medium containing VEGF, bFGF and a transforming growth factor beta (TGFP) signaling inhibitor.

[0092] Preferably, step 1a) is performed for 1-3 days. Preferably, step 1b) is performed for 2-4 days. Preferably step 1c) is performed for 4-10 days.

[0093] The GSK3 inhibitor is preferably one or more selected from the group consisting of CHIR99021, BIO (6-bromoindirubin-30-oxime), SB216763, CHIR-98014, CT98014, CT98023, CT99021, TWS119, SB41528, AR-A014418, AZD-1080, Alsterpaullone, Cazpaullone and Kenpaullone. In a preferred embodiment, the GSK3 inhibitor is CHIR99021. The GSK3 inhibitor, preferably CHIR99021, may be included in the medium at a concentration of 2-10 preferably 4-8 pM, more preferably 5-7 pM.

[0094] The VEGF concentration in the medium is preferably 5-95 ng / ml, preferably 25-75 ng / ml, more preferably 40-60 ng / ml. The bFGF concentration is preferably 1-40 ng / ml, preferably 10-30 ng / ml, more preferably 15-25 ng / ml.

[0095] The TGFp signaling inhibitor is preferably an Activin Receptor-like Kinase (ALK) receptor inhibitor, more preferably one or more selected from the group consisting of ALK5, ALK4, and ALK7 receptor inhibitors. For example, the ALK receptor inhibitor may be SB431542. In a preferred embodiment, the TGFp signaling inhibitor is SB431542. SB431542 can be represented by the following compound name: 4-[4-(2H-1,3-benzodioxol-5-yl)-5-(pyridin-2-yl)-1H-imidazole-2- 1] Benzamide. The TGFp signaling inhibitor, preferably, SB431542, may be included at a concentration of 1-20 pM, more preferably 5-15 pM.

[0096] The base medium in step 1) is not limited to a specific medium, and may be based preferably on RPMI1640 medium, which may further include antioxidants (such as AA2P, etc.) and / or B-27.

[0097] Step 1) as disclosed herein obtains HSCs, and which may further contain hematopoietic progenitor cells and megakaryocyte progenitor cells.

[0098] Step 2:

[0099] Preferably, in step 2) the number of CD41a- cells is at least 15%, more preferably at least 30% of the total cell number and / or the number of CD41a+ cells is less than 85%, preferably less than 70% of the total. This advantageously improves the efficiency of differentiation into megakaryocytes and platelet production.P37368PC00 / MCR - 11 -

[0100] Step 3:

[0101] Preferably, in step 3) the cells are cultured in a medium which contains thrombopoietin (TPO) and stem cell factor (SCF), more preferably further containing interleukin-3 (IL-3) and / or interleukin-6 (IL-6).

[0102] In an embodiment, in step 3) the TPO is present in the medium in a concentration of 50-150 ng / ml, preferably 80-120 ng / ml, more preferably 90-110 ng / ml. In an embodiment, the SCF is present in the medium in a concentration of 1-50 ng / ml, preferably 10-40 ng / ml, more preferably 20-30 ng / ml. In an embodiment, the IL-3 is present in the medium in a concentration of 1-20 ng / ml, preferably 5-15 ng / ml. In an embodiment, the IL-6 is present in the medium in a concentration of 1-20 ng / ml, preferably 5-15 ng / ml.

[0103] The medium in step 3) is not limited to a specific medium, and may preferably be based on IMDM (Iscove's Modified Dulbecco's Medium) medium, which may further include antioxidants (such as AA2P, etc.) and / or B-27. Step 3) is preferably performed for period of 2-4 days.

[0104] Step 4:

[0105] Preferably, in step 4) the cells are cultured in a medium which contains TPO. In an embodiment, in step 4) the TPO is present in the medium in a concentration of 50-150 ng / ml, preferably 80-120 ng / ml, more preferably 90-110 ng / ml. The medium in step 4) is not limited to a specific medium, and may be preferably based on IMDM (Iscove's Modified Dulbecco's Medium) medium, which may further include antioxidants (such as AA2P, etc.) and / or B-27. Step 4) is preferably performed for period of 3-7 days, preferably 4-6 days.

[0106] Step 4) obtains mature megakaryocytes or a culture medium containing megakaryocytes. In step 4), the megakaryocytes are preferably allowed to produce artificial platelets.

[0107] Step 5:

[0108] Step 5) is a step of obtaining artificial platelets from the culture medium obtained in step 4). The separation can be done by e.g. one or more steps of centrifugation, density gradient separation and filtration.

[0109] The term “artificial platelet lysate” in the context of the present invention means a composition derived from artificial platelets by their lysis by any appropriate means to release their intracellular contents, particularly intracellularly stored growth factors, cytokines, and other bioactive molecules. The artificial platelet lysate disclosed herein is preferably a human artificial platelet lysate.P37368PC00 / MCR - 12 -

[0110] The term “platelet protein” in the context of the present invention means any protein that is synthesized or stored naturally by platelets. The “platelet protein” as disclosed herein is more preferably produced by an artificial platelet protein or is an artificial platelet-derived protein, i.e. any protein that is synthesized or stored by an artificial platelet. The platelet protein or artificial platelet protein may include one or more of platelet-derived growth factor (PDGF)-AA, PDGF-BB, PDGF-AB, transforming growth factor beta 1 (TGF-pi), TGF-P2, brain-derived neurotrophic factor (BDNF), insulin-like growth factor 1 (IGF-1), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), basic Fibroblast Growth Factor (bFGF), epidermal growth factor (EGF), growth / differentiation factor 15 (GDF15), insulin-like growth factor-binding protein 1 (IGFBP-1), stem Cell Factor Receptor (SCF R) and TIMP metallopeptidase inhibitor 1 (TIMP1).

[0111] In embodiments, the total amount of platelet proteins in the platelet lysate composition is 0.001-10 mg / ml, preferably 0.01-5 mg / ml, more preferably 0.1 - 1 mg / ml. In preferred embodiments, the total amount of platelet proteins in the platelet lysate composition is 0.01-5 mg / ml, preferably 0.1-2 mg / ml, more preferably 0.5 - 1 mg / ml. This amount may advantageously provide for highest cell growth (in combination with the one or more proteins exogenous to platelets).

[0112] Proteins exogenous to platelets

[0113] The term “protein exogenous to platelets” means that said protein is not produced, stored, or released by platelets, more preferably artificial platelets as disclosed herein, but instead are introduced from another biological or synthetic source. The term “protein exogenous to platelets” in addition or alternatively encompasses proteins which are not naturally produced by platelets. For example, albumin is a plasma protein which is produced by the liver, and which is not produced by platelets. Hence, albumin is an example of a “protein exogenous to platelets” in the context of the present invention. There may be proteins that are produced by donor-derived platelets, but not by the artificial platelets (depending on how the artificial platelets are obtained). Hence, in preferred embodiments, the term “protein exogenous to platelets” refers to proteins which are exogeneous to artificial platelets (even though the protein is produced by donor-derived platelets). In more preferred embodiments, the term “protein exogenous to platelets” refers to proteins which are not exogenous to the artificial platelets as provided in the artificial platelet composition as disclosed herein, the artificial platelets from which the artificial platelet lysate as disclosed herein is derived, or the artificial platelets from which the protein composition as disclosed herein is derived.P37368PC00 / MCR - 13-

[0114] The platelet lysate composition as disclosed herein preferably has a total protein content and / or total plasma protein content of 1-250 mg / ml, preferably 10-150 mg / ml, more preferably 20 -100 mg / ml. In preferred embodiments, the platelet lysate composition as disclosed herein has a total protein content and / or total plasma protein content of 10-100 mg / ml, preferably 30-80 mg / ml. This amount may advantageously provide for highest cell growth (in combination with the platelet proteins).

[0115] In embodiments, the one or more proteins exogenous to platelets comprises one or more plasma proteins or is provided as one or more plasma proteins. The plasma protein in the context of the present invention encompasses one or more of albumin, globulins (e.g. a, p, y globulins), fibrinogen and other clotting factors, complement proteins, carrier / binding proteins, acute-phase proteins. The plasma protein as disclosed herein is preferably a protein which is produced by the liver. Preferably, the one or more plasma proteins comprises at least albumin, preferably albumin together with one or more further plasma proteins.

[0116] In embodiments, the one or more proteins exogenous to platelets, preferably one or more plasma proteins, more preferably albumin, are present in the artificial platelet lysate composition in amount of 1-250 mg / ml, preferably 10-150 mg / ml, more preferably 20-100 mg / ml. In preferred embodiments, the one or more proteins exogenous to platelets, preferably one or more plasma proteins, more preferably albumin, are present in the artificial platelet lysate composition in an amount of 10-100 mg / ml, preferably 30-80 mg / ml. The one or more plasma proteins and / or albumin is more preferably present in the artificial platelet lysate composition in an amount of 5 - 150 mg / ml, preferably 20- 100 mg / ml, more preferably 30 -80 mg / ml.

[0117] In embodiments, the one or more proteins exogenous to platelets is provided in, or provided as, a plasma, more preferably human plasma. In embodiments, the composition disclosed herein preferably comprises plasma, more preferably human plasma. The term “plasma” in the context of the present invention means the liquid, cell-free portion of blood that is obtained when anticoagulated blood is centrifuged to remove blood cells. It contains water, electrolytes, proteins, nutrients, hormones, waste products, and clotting factors, including fibrinogen. The plasma is preferably fibrinogen depleted, meaning that the plasma is treated to remove fibrinogen, for example achieved by clotting the plasma and then removing the clot. The plasma in the context of the present invention encompasses donor-derived plasma, including pooled plasma from multiple donors. The plasma in the context of the present invention most preferably is human plasma. The term “plasma” in the context of the present invention encompasses enriched plasma, i.e. blood plasma that has been concentrated orP37368PC00 / MCR - 14-

[0118] enhanced with specific components (e.g. proteins, or growth factors), so that their levels are increased beyond its natural range. In embodiments, the one or more proteins exogenous to platelets is provided in or as a serum, more preferably human serum. The term “serum” in the context of the present invention means the liquid portion of blood / plasma, but lacking clotting factors. The term “serum” in the context of the present invention encompasses enriched serum. The serum in the context of the present invention most preferably is human serum.

[0119] In embodiments, the artificial platelet lysate composition disclosed herein comprises 30 -99% (v / v), preferably 50 - 95 % (v / v), more preferably 70-90% (v / v) plasma and / or serum, preferably human plasma and / or human serum. In preferred embodiments, the artificial platelet lysate composition disclosed herein comprises 65-95% (v / v), preferably 70-90% (v / v), more preferably 75-85% (v / v) plasma and / or serum, more preferably human plasma and / or human serum.

[0120] In embodiments, the artificial platelet lysate composition as disclosed herein preferably comprises PDGF-AA, preferably 0.1-100 ng / ml, more preferably 1-10 ng / ml PDGF-AA. In addition or alternatively, the artificial platelet lysate composition as disclosed herein preferably comprises PDGF-BB, preferably 50 pg / ml-50 ng / ml, more preferably 0.5-5 ng / ml PDGF-BB. In addition or alternatively, the artificial platelet lysate composition as disclosed herein preferably comprises PDGF-AB, preferably 0.1-100 ng / ml, more preferably 1-10 ng / ml PDGF-AB. In addition or alternatively, the artificial platelet lysate composition as disclosed herein preferably comprises EGF, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml EGF. In addition or alternatively, the artificial platelet lysate composition as disclosed herein preferably comprises VEGF, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml VEGF. In addition or alternatively, the artificial platelet lysate composition as disclosed herein preferably comprises TGF-pi, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml TGF-pi. In addition or alternatively, the platelet lysate composition as disclosed herein preferably comprises TGF-P2, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml TGF-P2. In addition or alternatively, the artificial platelet lysate composition as disclosed herein preferably comprises HGF, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml HGF. In addition or alternatively, the artificial platelet lysate composition as disclosed herein preferably comprises bFGF, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml bFGF. In addition or alternatively, the artificial platelet lysate composition as disclosed herein preferably comprises GDF15, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml GDF15. In addition or alternatively, the artificial platelet lysate composition as disclosed herein preferably comprises IGFBP-1, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml IGFBP-1. In addition or alternatively, the artificial platelet lysate composition as disclosed herein preferably comprisesP37368PC00 / MCR - 15-

[0121] SCF R, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml SCF R. In addition or alternatively, the artificial platelet lysate composition as disclosed herein preferably comprises TIMP1, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml TIMP1.

[0122] In an embodiment, the artificial platelet lysate composition as disclosed herein is fibrinogen free and / or fibrinogen depleted.

[0123] In a preferred embodiment, the artificial platelet lysate composition comprises

[0124] - artificial platelet lysate providing platelet proteins such that the amount of platelet proteins is 0.01-5 mg / ml, preferably 0.1-2 mg / ml, calculated on the artificial platelet lysate composition and / or the total of the artificial platelet lysate and one or more proteins exogenous to platelets in the composition.

[0125] In a preferred embodiment, the artificial platelet lysate composition comprises

[0126] - one or more proteins exogenous to platelets, wherein the total amount of the one or more proteins exogenous to platelets is 5-200 mg / ml, preferably 10-100 mg / ml calculated on the artificial platelet lysate composition and / or the total of the artificial platelet lysate and one or more proteins exogenous to platelets in the composition.

[0127] In a preferred embodiment, the artificial platelet lysate composition comprises

[0128] - artificial platelet lysate providing platelet proteins such that the amount of platelet proteins is 0.01-5 mg / ml, preferably 0.1-2 mg / ml, calculated on the artificial platelet lysate composition and / or the total of the artificial platelet lysate and plasma in the composition.

[0129] In a preferred embodiment, the artificial platelet lysate composition comprises

[0130] plasma, wherein the amount of the plasma is 65-95% (v / v) calculated on the artificial platelet lysate composition and / or in an amount such that it provides total plasma proteins in an amount of 5-200 mg / ml, preferably 10-100 mg / ml calculated on the artificial platelet lysate composition and / or the total of the artificial platelet lysate and plasma in the composition.

[0131] Method of producing the artificial platelet lysate composition

[0132] In embodiments, the present invention pertains to a method of producing an artificial platelet lysate composition as disclosed herein, the method comprising the steps of providing an artificial platelet lysate as disclosed herein and combining it with, or supplementing with, the one or more proteins exogenous to platelets, preferably one or more plasma proteins, more preferably plasma.P37368PC00 / MCR - 16-

[0133] In embodiments, the artificial platelet lysate of the present disclosure is provided in a medium, preferably in a cell culture medium.

[0134] In embodiments, the method of producing the artificial platelet lysate composition, comprises the steps of

[0135] a) providing artificial platelets, preferably iPSC-derived artificial platelets;

[0136] b) lysing at least part of the artificial platelets to provide an artificial platelet lysate, preferably an iPSC-derived artificial platelet lysate;

[0137] c) combining the artificial platelet lysate with plasma in relative amounts disclosed herein. Preferably, the artificial platelet lysate provides platelet proteins in an amount of 0.01-5 mg / ml, calculated on the artificial platelet lysate composition and / or the total of the artificial platelet lysate composition and the plasma.

[0138] Preferably, the amount of plasma is 65-95% (v / v) and / or the plasma provides plasma proteins in an amount of 5-200 mg / ml, calculated on the artificial platelet lysate composition and / or total of the artificial platelet lysate composition and the plasma.

[0139] Protein composition and method of production thereof

[0140] In embodiments, the present invention pertains to a protein composition suitable for use in cell culture and / or as cell culture medium, wherein the protein composition comprises

[0141] - medium, preferably basal medium,

[0142] - artificial platelet lysate providing platelet proteins, and

[0143] - preferably one or more proteins exogenous to platelets.

[0144] The protein composition as disclosed herein is preferably a medium composition, more preferably a cell culture medium composition.

[0145] Medium

[0146] The term “medium” in the context of the present invention means a support for maintaining the viability and growth of cells, tissues, or biological products. The “medium” may be liquid, semi-solid, or scaffold-based, but is preferably a liquid medium. More preferably, the “medium” disclosed herein is a basal medium. The term "basal medium" in the context of the present invention means an aqueous solution for the support of cell survival and basic functions in cell culture, and containing at least essential amino acids, an energy source (e.g. carbohydrates), vitamins, inorganic compounds (e.g. salts such as sodium chloride, and sodium phosphate), and preferably one or more nucleotides, but which does not contain specialized additives growth factors or cytokines. The “medium” or “basal medium” may be forP37368PC00 / MCR - 17-

[0147] example Dulbecco’s Modified Eagle Medium (DMEM), Minimum Essential Medium (MEM), Roswell Park Memorial Institute Medium (RPMI-1640), Ham’s Nutrient Mixture F-10 or F-12 (Ham’s F-10 / F-12), Iscove’s Modified Dulbecco’s Medium (IMDM), Eagle’s Minimum Essential Medium (EMEM), Glasgow’s Modification of MEM (GMEM) or Leibovitz's L-15 Medium (L-15).

[0148] In embodiments, the medium is present in the composition as disclosed (e.g. platelet or protein composition) in an amount of 20-99% (v / v), preferably 50-98% (v / v), more preferably 75-97% (v / v), even more preferably 90-95% (v / v). For example, the medium may be present in the composition as disclosed herein in an amount of 90-97% (v / v), or 91-96%(v / v), or 92-95% (v / v).

[0149] The artificial platelet lysate as disclosed herein preferably has a total protein content of 0. QI-50 mg / ml, preferably 0.1-25 mg / ml, more preferably 1 - 10 mg / ml. In preferred embodiments, the artificial platelet lysate as disclosed herein has a total protein content of 0.01-20 mg / ml, preferably 0.1-10 mg / ml, more preferably 1 -5 mg / ml. In addition or alternatively, the artificial platelet lysate as disclosed herein preferably comprises PDGF-AA, preferably 0.1-100 ng / ml, more preferably 1-10 ng / ml PDGF-AA . In addition or alternatively, the artificial platelet lysate as disclosed herein preferably comprises PDGF-BB, preferably 50 pg / ml-50 ng / ml, more preferably 0.5-5 ng / ml PDGF-BB. In addition or alternatively, the artificial platelet lysate as disclosed herein preferably comprises PDGF-AB, preferably 0.1-100 ng / ml, more preferably 1-10 ng / ml PDGF-AB. In addition or alternatively, the artificial platelet lysate as disclosed herein preferably comprises EGF, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml EGF. In addition or alternatively, the artificial platelet lysate as disclosed herein preferably comprises VEGF, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml VEGF. In addition or alternatively, the artificial platelet lysate as disclosed herein preferably comprises TGF-pi, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml TGF-pi. In addition or alternatively, the artificial platelet lysate as disclosed herein preferably comprises TGF-P2, preferably 0.01 -10 ng / ml, more preferably 0.1-1 ng / ml TGF-P2. In addition or alternatively, the artificial platelet lysate as disclosed herein preferably comprises HGF, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml HGF. In addition or alternatively, the artificial platelet lysate as disclosed herein preferably comprises bFGF, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml bFGF. In addition or alternatively, the artificial platelet lysate as disclosed herein preferably comprises GDF15, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml GDF15. In addition or alternatively, the artificial platelet lysate as disclosed herein preferably comprises IGFBP-1, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml GDF15. In addition or alternatively, the artificial platelet lysate as disclosed herein preferably comprisesP37368PC00 / MCR - 18-

[0150] SCF R, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml SCF R. In addition or alternatively, the artificial platelet lysate as disclosed herein preferably comprises TIMP1, preferably 0.01 - 10 ng / ml, more preferably 0.1-1 ng / ml TIMP1.

[0151] In embodiments, the platelet lysate is provided in the composition in an amount such that it provides for a total amount of platelet proteins of 0.001-10 mg, preferably 0.001-1 mg, more preferably 0.01 - 0.1 mg, per ml composition (e.g. platelet or protein composition as disclosed herein). In preferred embodiments, the platelet lysate is provided in the composition such that it provides for a total amount of platelet proteins of 0.005-2 mg, preferably 0.01-1 mg, more preferably 0.05 - 0.5 mg, wherein the amount is per ml composition. This amount may advantageously provide for highest cell growth (in combination with the one or more proteins exogenous to platelets).

[0152] In an embodiment, PDGF-AA is provided in the composition disclosed herein (e.g. protein composition, artificial platelet composition) in an amount of 0.01-10 ng / ml, more preferably 100-1000 pg / ml. In an embodiment, PDGF-BB is provided in the composition disclosed herein in an amount of 5-5000 pg / ml, more preferably 50-500 pg / ml. In an embodiment, PDGF-AB is provided in the composition disclosed herein in an amount of 0.01-10 ng / ml, more preferably 100-1000 pg / ml. In an embodiment, EGF is preferably provided in the composition disclosed herein in an amount of 0.1-1000 pg / ml, more preferably 1-100 pg / ml. In an embodiment VEGF is preferably provided in the composition disclosed herein in an amount of 0.1-1000 pg / ml, more preferably 1-100 pg / ml. In an embodiment, TGF-pi is preferably provided in the composition disclosed herein in an amount 0.1-1000 pg / ml, more preferably 1-100 pg / ml. In an embodiment, TGF-pi is preferably provided in the composition disclosed herein in an amount 0.1-1000 pg / ml, more preferably 1-100 pg / ml. In an embodiment, HGF is preferably provided in the composition disclosed herein in an amount 0.1-1000 pg / ml, more preferably 1-100 pg / ml. In an embodiment, bFGF is preferably provided in the composition disclosed herein in an amount 0.1-1000 pg / ml, more preferably 1-100 pg / ml. In an embodiment, GDF15 is preferably provided in the composition disclosed herein in an amount 0.1-1000 pg / ml, more preferably 1-100 pg / ml. In an embodiment, IGFBP-1 is preferably provided in the composition disclosed herein in an amount 0.1-1000 pg / ml, more preferably 1-100 pg / ml. In an embodiment, SCF R is preferably provided in the composition disclosed herein in an amount 0.1-1000 pg / ml, more preferably 1-100 pg / ml. In an embodiment, TIMP1 is preferably provided in the composition disclosed herein in an amount 0.1-1000 pg / ml, more preferably 1-100 pg / ml.P37368PC00 / MCR - 19-

[0153] In embodiments, the composition disclosed herein (e.g. protein composition, artificial platelet composition) comprises 0.1 -20% (v / v), preferably 0.5 - 10% (v / v), more preferably 1.0-5% (v / v) artificial platelet lysate.

[0154] In embodiments, the composition as disclosed herein is fibrinogen free and / or fibrinogen depleted.

[0155] Proteins exogenous to platelets

[0156] In embodiments, the one or more proteins exogenous to platelets are provided in the composition (e.g. protein or platelet composition disclosed herein) in amount of 0.1 - 100 mg, preferably 0.5-50 mg, more preferably 1.0 - 25 mg, most preferably 2.0 - 10 mg, wherein the amount is the total protein per ml composition. In embodiments, the composition disclosed herein (e.g. protein or platelet composition disclosed herein) has a total protein content of 0.1 - 100 mg, preferably 0.5-50 mg, more preferably 1.0 -25 mg, most preferably 2.0 - 10 mg, wherein the amount is the total protein per ml composition.

[0157] In embodiments, the one or more proteins exogenous to platelets comprises one or more plasma proteins or is provided as one or more plasma proteins, preferably in an amount of 0.5-50 mg, more preferably 1.0 - 25 mg, most preferably 2.0 - 10 mg, wherein the amount is the total protein per ml composition. In embodiments, the one or more plasma proteins comprises albumin in an amount of 0.5-50 mg / ml, preferably 1-25 mg / ml, more preferably 2-10 mg / ml, even more preferably 3-5 mg / ml, calculated on the composition disclosed herein (e.g. protein or artificial platelet composition disclosed herein). The albumin is more preferably in an amount of 0.2 - 5.0 mg / ml, preferably 0.5 - 2.5 mg / ml, more preferably 1-2 mg / ml, calculated on the composition disclosed herein (e.g. protein or artificial platelet composition disclosed herein).

[0158] In embodiments, the composition disclosed herein comprises 0.1 -25% (v / v), preferably 0.5 - 10% (v / v), more preferably 1-5% (v / v) plasma and / or serum, preferably human plasma and / or human serum. In preferred embodiments, the composition disclosed herein comprises 2-20% (v / v), preferably 1-15% (v / v), more preferably 2-10% (v / v) human plasma.

[0159] In a preferred embodiment, the protein composition comprises

[0160] - medium, preferably basal medium, in an amount of 75-97% (v / v) calculated on the composition,

[0161] - artificial platelet lysate providing platelet proteins such that the total amount of platelet proteins is 0.001-1 mg / ml, preferably 0.01-0.1 mg / ml, calculated on the composition, andP37368PC00 / MCR - 20 -

[0162] - one or more proteins exogenous to platelets, wherein the total amount of the one or more proteins exogenous to platelets is 0.5-50 mg / ml, preferably 1.0-10 mg / ml calculated on the composition.

[0163] In a preferred embodiment, the protein composition comprises,

[0164] - medium, preferably basal medium, in an amount of 75-97% (v / v) calculated on the composition,

[0165] - artificial platelet lysate providing platelet proteins such that the total amount of platelet proteins is 0.001-1 mg / ml, preferably 0.01-0.1 mg / ml, calculated on the composition, and - plasma providing one or more proteins exogenous to platelets, wherein the amount of the plasma is 1-20% (v / v), preferably 5-15% (v / v) and / or in an amount such that it provides total plasma proteins in an amount of.5-50 mg / ml, preferably 1.0-10 mg / ml calculated on the composition.

[0166] Method of producing the protein composition

[0167] In embodiments, the present invention pertains to a method of producing a protein composition (e.g. cell culture medium) as disclosed herein, the method comprising the steps of providing the artificial platelet composition (e.g. starting material) as disclosed herein and lysing at least part of the artificial platelets. The lysis or lysing of platelets as disclosed herein may be by any suitable means capable of rupturing the platelet membrane and releasing at least part of the stored content. Preferably, the lysis or lysing is by one or more method selected from the group consisting of freeze-thawing, sonication, mechanical disruption, osmotic lysis and chemical lysis. More preferably, the lysis or lysing is by repeatedly freezethawing.

[0168] In embodiments, the present invention pertains to a method of producing a protein composition as disclosed herein, the method comprising the steps of providing the platelet lysate composition as disclosed herein and combining it with medium, preferably basal medium.

[0169] In embodiments, the present invention pertains to method of producing a medium composition suitable for cell culture, the method comprising the steps of:

[0170] a) providing artificial platelets, preferably iPSC-derived artificial platelets;

[0171] b) lysing at least part of the artificial platelets to provide an artificial platelet lysate, preferably an iPSC-derived artificial platelet lysate;

[0172] c) combining the artificial platelet lysate with plasma and basal medium to obtain the medium composition, in relative amounts disclosed herein.P37368PC00 / MCR - 21 -

[0173] Preferably, step c) is performed such that the amount of artificial platelet lysate is 0.001-1 mg / ml, preferably 0.01-0.1 mg / ml, calculated on the medium composition.

[0174] Preferably, step c) is performed such that the amount of plasma is 1-20% (v / v), preferably 5-15% (v / v) and / or in an amount such that it provides plasma proteins in an amount of 0.5-50 mg / ml, preferably 1.0-10 mg / ml, calculated on the medium composition.

[0175] Preferably, step c) is performed such that the amount of basal medium is 75-97% (v / v), calculated on the medium composition.

[0176] Artificial platelet composition and method of production thereof

[0177] In embodiments, the present invention pertains to an artificial platelet composition which is suitable for preparation of the protein composition as disclosed herein, the artificial platelet composition comprising

[0178] - medium, preferably a basal medium,

[0179] - artificial platelets, and

[0180] - preferably one or more proteins exogenous to platelets.

[0181] The artificial platelet composition may form a starting material (or precursor medium) for the artificial platelet composition disclosed herein. The term “starting material” in the context of the present invention means a pre-formulated base solution which sustains artificial platelet growth factors until the artificial platelets are lysed. After lysis of the platelets in the starting material, the starting material can be converted into a final, ready-to-use medium, e.g. a cell culture medium as disclosed herein.

[0182] The medium, platelet lysate, artificial platelets or one or more proteins exogenous to platelets are preferably as disclosed herein in the context of the protein composition.

[0183] In an embodiment, the artificial platelets are present in the artificial platelet composition in an amount of 1x105- 1x1010, preferably 1x106- 1x109, 1x107- 1x108artificial platelets per ml composition. These amounts of artificial platelets may advantageously provide for highest cell growth.

[0184] In embodiments, the present invention pertains to a method for producing the artificial platelet composition as disclosed herein, the method comprising combining artificial platelets as disclosed herein together with the one or more proteins exogenous to platelets, preferably plasma proteins, more preferably plasma in medium.P37368PC00 / MCR - 22 -

[0185] In a preferred embodiment, the artificial platelet composition comprises

[0186] - medium, preferably basal medium, in an amount of 75-97% (v / v) calculated on the composition,

[0187] - artificial platelets, in an amount of 1x105- 1x1010, preferably 1x106- 1x109, 1x107- 1x108platelets per ml artificial platelet composition, and

[0188] - one or more proteins exogenous to platelets, wherein the total amount of the one or more proteins exogenous to platelets is 0.5-50 mg / ml, preferably 1.0-10 mg / ml calculated on the composition.

[0189] In a preferred embodiment, the artificial platelet composition comprises,

[0190] - medium, preferably basal medium, in an amount of 75-97% (v / v) calculated on the composition,

[0191] - artificial platelets, in an amount of 1x105- 1x101°, preferably 1x106- 1x109, 1x107- 1x108platelets per ml artificial platelet composition,

[0192] and

[0193] - plasma, wherein the amount of the plasma is 1-20% (v / v), preferably 5-15% (v / v) and / or in an amount such that it provides total plasma proteins in an amount of 0.5-50 mg / ml, preferably 1.0-10 mg / ml calculated on the composition.

[0194] Kit-of-parts

[0195] In embodiments, the present invention pertains to a kit-of-parts suitable for the preparation of the artificial platelet composition (e.g. starting material) or the protein composition (e.g. cell culture medium) disclosed herein, the kit-of-parts comprising

[0196] - medium, preferably basal medium,

[0197] - artificial platelets, preferably provided in a liquid suspension,

[0198] - medium comprising one or more proteins exogenous to platelets, preferably plasma proteins, more preferably plasma.

[0199] The liquid suspension for the artificial platelets is preferably a storage solution or preservation medium for platelets.

[0200] The artificial platelets are preferably provided in the kit-of-parts in an amount of 1x105-1x1010, preferably 1x106- 1x109, more preferably 1x107- 1x108artificial platelets per ml medium provided in the kit-of-parts. The one or more proteins exogenous to platelets are preferably provided in the kit-of-parts in a total amount of 0.5 - 50 mg, preferably 1.0 - 10 mg per ml medium provided in the kit-of-parts.P37368PC00 / MCR - 23 -

[0201] In a preferred embodiment, the kit-of-parts comprises

[0202] - medium, preferably basal medium,

[0203] - artificial platelets in a liquid suspension, in an amount of 1x105- 1x1010, preferably 1x106-1x109, more preferably 1x107- 1x108, artificial platelets per ml medium provided in the kit-of parts, and

[0204] - plasma, in an amount of 1-20% (v / v), preferably 5-15% (v / v) and / or in an amount such that it provides total plasma proteins in an amount of 0.5-50 mg / ml, preferably 1.0-10 mg / ml, wherein the amount is the amount per ml medium provided in the kit-of parts.

[0205] In embodiments, the present invention pertains to a method for producing an artificial platelet composition (e.g. starting material) using the kit-of-parts disclosed herein, the method comprising the step of combining the artificial platelets with the medium and the one or more proteins exogenous to platelets, preferably plasma proteins, more preferably plasma.

[0206] Further additives

[0207] The present inventors found that providing further additives in the compositions of the invention may be beneficial in enhancing the bioactivity of the artificial platelet lysate, in particular in combination with the exogenous proteins, more particularly plasma.

[0208] For example, the present inventors found that heparin and / or heparin sulfate not only provide for anticoagulation in the platelet- or lysate- compositions, but also further enhances the cell growth in combination with the artificial platelet lysate. Compositions based on platelet lysate, plasma and heparin and / or heparin sulfate may provide for highest stimulatory effect on cell growth. The present inventors consider that dextran sulphate or fucoidan can be used as alternative to heparin and may provide similar stimulatory effects as heparin in the compositions. It is considered by the present inventors that said anticoagulant factors may promote the proliferation and / or differentiation in certain cell types including stem cells.

[0209] In embodiments, the composition as disclosed herein (e.g. platelet lysate, protein, platelet composition) further comprises one or more anticoagulants, preferably heparin and / or heparin sulfate, fucoidan, and / or dextran (e.g. dextran sulphate). The heparin is preferably provided in the artificial platelet lysate composition in an amount of 1 - 100 ll / rnl, preferably 5-60 ll / rnl, more preferably 10-30 ll / rnl. The heparin and / or heparin sulfate is preferably provided in the protein or artificial platelet composition in an amount of 0.1 - 10 ll / rnl, preferably 0.5 - 5 ll / rnl, more preferably 1-3 ll / rnl. The dextran is preferably provided in the artificial platelet lysate composition in an amount of 1- 200 pg / ml, preferably 10-100 pg / ml, more preferably 20 - 150P37368PC00 / MCR - 24 -

[0210] pg / ml. The dextran is preferably provided in the protein or artificial platelet composition in an amount of 0.1-100 pg / ml, preferably 1- 20 pg / ml, more preferably 2- 15 g / ml.

[0211] The fucoidan is preferably provided in the artificial platelet lysate composition in an amount of 1- 200 pg / ml, preferably 10-100 pg / ml, more preferably 20 - 150 pg / ml. The fucoidan is preferably provided in the protein or artificial platelet composition in an amount of 0.1-100 pg / ml, preferably 1- 20 pg / ml, more preferably 2- 15 pg / ml.

[0212] The heparin or heparin sulfate, fucoidan and / or dextran (e.g. dextran sulphate) are preferably provided in combination with artificial platelet lysate and plasma as this may advantageously lead to highest cell growth. The dextran as disclosed herein is most preferably dextran sulphate sodium (DSS).

[0213] In embodiments, the composition as disclosed herein (e.g. platelet lysate, protein, artificial platelet composition) further comprises one or more polysaccharides selected from the group consisting of hyaluronic acid, alginate, chitosan, agarose and pectin. The polysaccharide is preferably provided in the protein or artificial platelet composition in an amount of 10-500 pg / ml, preferably 50-200 pg / ml.

[0214] In addition or alternatively, the present inventors found that activating the artificial platelets with thrombin or platelet activating factor (PAF), or the like, before preparation the lysate can achieve an improved lysate. Without being bound by theory, the stimulation of the artificial platelets appears to lead to a richer and / or more consistent growth factor profile, which can be more beneficial for cell culture. The present inventors consider it particularly advantageous to include stimulatory factors for platelets when there may be a reduced concentration of platelet proteins (i.e. growth factors) present in the lysate, for example with the use of further diluent solutions (e.g. Plasma-Lyte) and / or when using lower concentrations of artificial platelets to produce the lysate. The one or more polysaccharides are preferably provided in combination with artificial platelet lysate and plasma as this may advantageously lead to highest cell growth.

[0215] In embodiments, the composition as disclosed herein (e.g. artificial platelet lysate, protein, artificial platelet composition) further comprises one or more of thrombin and platelet-activating-factor (PAF).

[0216] The thrombin is preferably provided in the artificial platelet lysate composition in an amount of 0.1- 5 ll / rnl, preferably 0.5-2 ll / rnl. The thrombin is preferably provided in the protein or artificial platelet composition in an amount of 0.005-0.25 ll / rnl, preferably 0.025-0.1 ll / rnl. The PAF is preferably provided in the artificial platelet lysate composition in an amount of 1-500 nM, preferably 10-100 nM. The PAF is preferably provided in the protein or artificial platelet composition in an amount of 0.1 - 25 ll / rnl, preferably 1-5 nM.P37368PC00 / MCR - 25 -

[0217] The present inventors furthermore found that it is advantageous to include one or more NAD+ precursors in the compositions of the invention. The term “NAD+ precursor” in the context of the present invention means compounds like nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) or nicotinamide (NAM), that are metabolized into NAD+via salvage or de novo biosynthesis pathways. Without being bound by theory, the present inventors consider that the NAD+ precursor may promote the proliferation and / or differentiation in certain cell types including stem cells.

[0218] The NR and / or NMN is preferably provided in the artificial platelet lysate composition in an amount of 100-50000 pM, preferably 1000 - 5000 pM. The NR and / or NMN is preferably provided in the protein or artificial platelet composition in an amount of 10 - 5000 pM, preferably 100-500 pM.

[0219] The NAM is preferably provided in the artificial platelet lysate composition in an amount of 1-500 mM, preferably 10-50 mM. The NAM is preferably provided in the protein or artificial platelet composition in an amount of 0.1-50 mM, preferably 1-5 mM.

[0220] Use

[0221] In an aspect, the present invention pertains to a use the composition as disclosed herein (e.g. artificial platelet lysate, protein, artificial platelet composition), preferably in one or more selected from the group consisting of cell culture, cell therapy, gene therapy, a tissue-engineered product and advanced medicinal product (ATMP).

[0222] Without being bound by theory, the present inventors consider that the compositions disclosed herein may promote cell growth, healing, and tissue regeneration both in vitro (e.g. in cell cultures) or in vivo (e.g. in cell therapy, gene therapy, a tissue-engineered product, an ATMP). These compositions disclosed herein may mimic and in vivo environment promoting natural biological processes.

[0223] In preferred embodiments, the composition as disclosed herein (e.g. artificial platelet lysate, protein, artificial platelet composition) is used as cell culture supplement. The term “cell culture supplement” in the context of the present invention means any substance or composition with the purpose of adding to a base medium for cell culture, and which acts to enhance one or more cell growth, viability and / or functionality.

[0224] The cell in the context of the current invention is not limited to a certain type, and can be one or more selected from the group consisting of a hematopoietic cell (e.g. erythroid cell, hematopoietic stem cell), myeloid cell (e.g. granulocyte, megakaryocyte, macrophage),P37368PC00 / MCR - 26 -

[0225] immune cell (e.g. neutrophil, natural killer cell, T lymphocyte, B lymphocyte, monocyte, dendritic cell), Chimeric Antigen Receptor T cell (CAR T cell), peripheral blood mononuclear cell (PBMCs), stem cell (e.g. hematopoietic stem cell, induced pluripotent stem cell (iPSC), an endothelial cell (EC), mesenchymal stem cell (MSC), embryonic stem cell), an amniotic epithelial cell, a hepatocyte, and a hepatic stellate cell. In an embodiment, the cell is preferably a human cell. In an embodiment, the cell is preferably a primary cell. In addition or alternatively, the cell as disclosed herein is used in an advanced medicinal product (ATMP).

[0226] The compositions of the invention were found to be particularly advantageous in the support in the culture of stem cells, more particularly mesenchymal stem cells. Without being bound by theory, the present inventors consider the compositions of the invention may provide for a growth factor composition in particularly favourable for MSC survival and growth. According, the cell in the context of the present invention is more preferably an MSC, such as a bone marrow MSC (BM-MSC), an adipose tissue MSC (AT-MSC), a Wharton's Jelly MSC (WJ-MSC), an umbilical cord MSC (LIC-MSC), a placenta MSC (PL-MSC) or a dental pulp MSC (DP-MSC), most preferably a BM-MSC or AT-MSC.

[0227] In embodiments, the present disclosure pertains to a method of culturing cells, preferably a stem cell as disclosed herein. The method of culturing cells preferably comprises culturing the cell in a cell culture medium, wherein the cell culture medium is a protein composition as disclosed herein.

[0228] In embodiments, the composition as disclosed herein is used non-therapeutically.

[0229] In embodiments, the composition as disclosed herein for use as a medicament.

[0230] In embodiments, the composition as disclosed herein is used in a method of treatment.

[0231] General definitions

[0232] - The terms ‘comprising’ or ‘to comprise’ and their conjugations, as used herein, refer to a situation wherein said terms are used in their non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. It also encompasses the more limiting verb ‘to consist essentially of’ and ‘to consist of’.

[0233] - Reference to an element by the indefinite article ’a’ or ‘an’ does not exclude the possibility that more than one of the elements is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article ‘a’ or ‘an’ thus usually means ‘at least one’.P37368PC00 / MCR - 27 -

[0234] - The terms ‘to increase’ and ‘increased level’ and the terms ‘to decrease’ and ‘decreased level’ (or to ‘reduce” and “reduced level”) preferably refer to a change of at least 5%, such as 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% higher or lower, respectively, than the corresponding level in a control or reference. In addition or alternatively, a level in a sample may be increased or decreased when it is statistically significantly increased or decreased compared to a level in a control or reference, irrespective of the size of change.

[0235] FIGURE LEGENDS

[0236] Figure 1. Cell morphology for different cell culture supplements at the 1st, 2ndor 3rdpassage of culture of adipose tissue mesenchymal stem cells. In the “iHPL” group, (i.e. induced human platelet lysate alone) no viable cells were observed anymore after the 2ndpassage, as indicated by the cross.

[0237] Figure 2. Cumulative population doubling (CPD) for different cell culture supplements after 10 days of culture of adipose tissue mesenchymal stem cells.

[0238] Figure 3. Doubling time (hours) for different cell culture supplements at the 1st, 2ndor 3rdpassage.

[0239] Figure 4. Total protein content (g / dl) for different cell culture supplements as determined with the BCA assay.

[0240] Figure 5. Relative albumin content normalized to the plasma condition (%) for different cell culture supplements as determined with ELISA

[0241] EXAMPLES

[0242]

[0243] 1 : first method for and characterisation of hiPSC-derived

[0244]

[0245] Human iPSC-derived platelets are produced and characterised as also already described in W02024076030A1. The detailed procedure is as follows.

[0246] Preparation of hiPSC

[0247] Human iPSC are placed in a T75 flask at a density of 4500 cells / cm2in mTeSR plus culture medium with 10 pg / ml of ROCK inhibitor (Y-27632) and cultured at a temperature of 37°C and 5% CO2 conditions. After 24 hours of culture, the cells are washed once with PBS to remove Y-27632, and the mTeSR plus culture medium is replenished. The culture medium is replaced once a day and cultured for 3 days to obtain hiPSC.P37368PC00 / MCR - 28 -

[0248] The obtained hiPSC are cultured in RPMI1640 basic medium containing 300 pM AA2P and 2% B-27 and medium containing 6 pM CHIR99021, a GSK3 inhibitor, at a temperature of 37°C and 5% CO2 conditions for 2 days. Culture medium is replaced once a day.

[0249] Afterwards, the medium composition is changed to RPMI1640 basic medium containing 300 pM AA2P and 2% B-27 and medium containing 50 ng / ml VEGF and 20 ng / ml bFGF, and incubated at 37°C for 3 days in 5% CO2 incubator. Culture medium is replaced once a day. Culture is continued until the cell confluency is approximately 70% or more. Afterwards, RPMI1640 basic medium containing 300 pM AA2P and 2% B-27 and 10 pM SB431542 along with VEGF and bFGF are added and cultured for an additional 4-10 days.

[0250] The floating cell population thus generated are cultured and added to IM DM basic medium containing 300 pM AA2P and 2% B-27 at a density of 1 ng / ml SCF, 10 ng / ml IL-3, and 10 ng / ml IL-6 are added and cultured for 3 days at 37°C and 5% CO2 . Afterwards, the medium composition is changed from IMDM basic medium containing 300 pM AA2P and 2% B-27 to medium containing 100 ng / ml TPO and further cultured for 5 days to perform the megakaryocyte maturation step and the cell suspension is obtained.

[0251] The cell suspension is collected and centrifuged at 300 x g for 3 minutes. The sediment is separated into megakaryocytes and the suspended matter is separated into platelets, and analysis of the platelets is performed.

[0252] Characterisation of hiPSC-derived platelets

[0253] Using FACS analysis, it is confirmed that the precipitated cells (considered to be the megakaryocytes) have positive expression of megakaryocyte-specific markers CD41a, CD42b, and CD61), indicating that the floating cells are differentiated into megakaryocytes and producing platelets.

[0254] It is confirmed that cells precipitated by centrifugation (considered to be the platelets) are activated by adenosine diphosphate (ADP) treatment, i.e. resulting in increased expression of PAC-1 and CD62p as demonstrated by FACS analysis.P37368PC00 / MCR - 29 -

[0255] 2: Second method for and characterisation of hiPSC-derived

[0256] hiPSC-derived platelets are produced and characterised as also already described in CN118256430A. The detailed procedure is as follows.

[0257] Preparation of hiPSC

[0258] iPSCs are cultured in culture dishes pre-coated with human recombinant laminin (rhLaminin-521). The culture medium is Essential 8 medium supplemented with 30 ng / mL VEGF-A165, 10 ng / mL bFGF, 5 pM Y-27632, 2 mM Chir-99021 and 20 ng / mL Activin A. The culture time is 2 days.

[0259] The medium is then replaced with hematopoietic differentiation medium (HDM) with the following formula: 1xlTS, 1x glutamax, 0.45 mM monothioglycerol, 50 g / mL ascorbic acid, and 20% KO-SRM in Iscove modified Dulbecco (IMDM). Thereafter, 30 ng / mL VEGF-A165, 10 ng / mL bFGF, 20 ng / mL BMP4, 5 pM Y-27632, and 20 ng / mL Activin A are added, and the culture is continued for 4 days.

[0260] The culture medium is then replaced with HDM medium supplemented with 50 ng / mL stem cell factor (SCF), 50 ng / mL thrombopoietin (TPO), 2 U / mL erythropoietin (EPO), and 5 pM Y-27632. The culture is continued for 8 days. The floating cell population is collected and centrifuged at 1000 rpm / min for 5 minutes.

[0261] The hematopoietic progenitor stem cells thus obtained in are plated in a culture dish precoated with 0.1% gelatin. The culture medium is HDM culture medium supplemented with 50 ng / mL thrombopoietin (TPO), 20 ng / mL IL-3, 20 ng / mL IL-6, 50 ng / mL IL-21, 5 nM Zemetostat, 200 nM Eltrombopag and 200 nM iBET151 (BET inhibitor). The culture is continued for 15-20 days. The floating cell population considered to be megakaryocytes are then collected.

[0262] The megakaryocytes obtained are transferred to a low-adsorption material culture flask / shaking flask, and the culture medium is replaced with HDM supplemented with 50 ng / mL thrombopoietin (TPO), 50 ng / mL stem cell factor (SCF), 50 ng / mL IL-21 and 5 pM Y-27632, and placed on a horizontal shaking shaker for expansion, and the rotation speed is adjusted to 120-150 rpm. The megakaryocytes can be expanded in vitro for several months. The subculture cycle is 3 days and the seeding density is 5x106 / mL each time.P37368PC00 / MCR - 30 -

[0263] The megakaryocytes obtained are suspended in platelet culture medium (PM) supplemented with 50 ng / mL thrombopoietin (TPO) and 5 pM Y-27632. The PM medium has the composition: Iscove modified Dulbecco (IMDM) with the addition of 1xlTS, 1x glutamax, 0.45 mM monothioglycerol, 50 g / mL ascorbic acid, 10 II heparin, and 5% human plasma. Static culture is performed for 1 day.

[0264] The culture medium is replaced with PM medium, supplemented with 50 ng / mL thrombopoietin (TPO), 0.5 ng / mL collagen, 5 nM Fingolimod HCI and 5 pM Y-27632. Static culture is performed for 1 day and then cells are cultured on a horizontal shaking shaker for another day with the rotation speed adjusted to 120-150 rpm.

[0265] The megakaryocytes obtained in the above steps are transferred to a bioreactor for platelet maturation in a 1 L system reactor and culture is continued for 5 to 6 days in a culture environment of 37°C and 5% CO2 . The maximum horizontal liquid flow linear velocity in the reactor is 30 cm / sec. The reactor specifications are as follows: cylindrical structure, external tank height 160 mm, bottom diameter 130mm, culture container thickness 5 mm; embedded multi-layer movable grid structure, variable direction rotational motion, rotation speed 120-150 rpm, maximum liquid flow linear velocity 30 cm / second.

[0266] Characterisation of hiPSC-derived platelets

[0267] The generation of megakaryocytes and functional platelets are confirmed using the methods as described under Example 1.

[0268] Example 3: Effects of cell culture supplements on cell culture

[0269] Method

[0270] Cell culture supplements

[0271] The cell culture supplements as tested in present Example are as according to Table 1.P37368PC00 / MCR - 31 -

[0272] Table 1. Overview of cell culture supplements tested. hPU=human platelet units (= 3 x 1011platelets in 250 mL)

[0273] Supplement condition Preparation Final concentration in medium (% v / v)

[0274] “Donor-derived HPL” • 5% lysate (-0.05 hPU) Donor-derived human platelet

[0275] lysate (-1 hPU)

[0276] “Plasma” • 5% plasma

[0277] Human plasma

[0278] “iHPL” - 500 pL platelet solution + • -0.6 % platelet lysate induced human platelet lysate 3625 pl PBS (« 1 hPU) (-0.05 hPU) without plasma - lysis and centrifugation

[0279] - 12 pl Heparin added (to 2

[0280] U / mL)

[0281] “iHPL composition” -700 pL platelet solution + • -0.6 % platelet lysate induced human platelet lysate 5075 pl fibrinogen-depleted (-0.05 hPU)

[0282] + human plasma plasma (~1 hPU) • -4.4% plasma

[0283] - lysis and centrifugation

[0284] - 0.4 pl / ml Heparin (stock

[0285] solution 5000 U / ml) added

[0286] (to 2 U / mL)

[0287]

[0288] Induced platelet lysate is prepared by resuspending induced platelets obtained according to Example 1 in liquid medium until a concentration of -1.2 x109platelets / ml. The platelet solutions are freeze / thawed (-80°C / 37°C, two times), centrifuged, and the supernatant is recovered.

[0289] The induced platelet lysate is either or not supplemented with fibrinogen-depleted human plasma prepared according to the method:

[0290] human donor plasma is supplemented 2 U / rnL human thrombin and 6.25 mM CaCh, and incubated at 37°C for 1 h. The formed clot is disrupted and centrifuged at 4000 x g for 5 min. The supernatant is obtained and sterile filtered (0,2 pm).

[0291] Donor-derived human platelet lysate (denoted herein as “Donor-derived HPL”, total protein content ~5-6 g / dl) was used as positive control. Fibrinogen-depletion was performed for the platelet lysate according to STM protocol:

[0292] - Add 6.25 mM CaCh + 0.02% w / v silica beadsP37368PC00 / MCR - 32 -

[0293] Incubate at 37°C for 1.5 h

[0294] Store fibrin clot overnight

[0295] Disrupt clot and centrifuge at 4.000 x g for 15 min

[0296] Sterile filter (0.2 pm) supernatant

[0297] Human plasma (total protein content ~4-5 g / dl) was used as negative control

[0298] In the platelet conditions, the number of platelets in the stock lysate equals - 1hPU (human platelet units, » 3 x 1011platelets in 250 mL). After dilution of the stock lysate in culture medium at 5% (v / v), this results in -0.05 hPU in the culture medium.

[0299] Heparin (2 ll / rnl) was added in all conditions comprising plasma.

[0300] Cell culture protocol

[0301] Adipose tissue-derived mesenchymal stem cell (MSCs) are seeded at 5000 cells / cm2in cell culture plates in alpha-MEM medium. 5% (v / v) of the supplements is added to the medium, as prepared according to the groups and concentrations denoted in Table 1. The cells are passaged every four days. Cell count and viability is determined at each passage. Cells are cultured for a total of 10 days.

[0302] Cell morphology was determined by light microscopy at each passage.

[0303] The cumulative population doubling was determined on days 3, 7 and 10 of culture.

[0304] Results

[0305] Figure 1 shows the morphology for the different cell culture supplements at the 1st, 2ndor 3rdpassage of culture. As expected, the “Donor-derived HPL” group showed an improved cell morphology over the “Plasma” group. In the “iHPL” group (induced human platelet lysate alone), no viable cells were observed anymore after the 2ndpassage, indicating that the lysate by itself could not support cell viability. However, in the “iHPL composition” group (induced human platelet lysate+plasma), excellent cell growth cell morphology was observed which surprisingly even outperformed that of the “Donor-derived HPL” group.

[0306] Table 2 shows the cumulative population doubling (CPD) for different cell culture supplements after 3, 7 or 10 days of culture. On day 3, the CPD was higher for the “Donor-derived HPL” and “iHPL composition” groups compared to the “Plasma” group. The “iHPL” group showed a poor CPD.P37368PC00 / MCR - 33 -

[0307] On days 7 and 10, no cell growth was seen anymore in the “iHPL”. In line with their improved cell morphology, the “iHPL composition” group showed the highest CPD (8.5 and 12, respectively) of all groups which outperformed that of the “Donor-derived HPL” group (7.0 and 9.0, respectively). The CPD at day 10 of culture is also shown in Figure 2.

[0308] Table 2: cumulative population doubling (CPD) for different cell culture supplements after 3, 7 or 10 days of culture.

[0309] Plasma Donor-derived iHPL iHPL

[0310] HPL composition Culture day

[0311] 3 1.5 3.5 <1 3.9

[0312] 7 3.0 7.0 no cell growth 8.5

[0313] 10 3.7 9.0 no cell growth 11.6

[0314]

[0315] Figure 3 shows the doubling time (hours) for the different cell culture supplements at the 1st, 2ndor 3rdpassage of culture. The “iHPL composition” group has the lowest doubling time of all groups in each of the passages, indicating that it promotes highest cell growth.

[0316] Plasma-Lyte 148 is often added to platelets as a storage or resuspension medium. To investigate the effect of dilution of iHPL with Plasma-Lyte 148, iHPL was diluted with a solution containing 70% plasma / 30% Plasma-lyte 148 (3625 pl per 500 pl platelet solution). The Plasma-Lyte (injection solution; pH 7.4; prod, by Baxter) has the following composition (per 1000 mL): sodium chloride (5.26 g), sodium gluconate (5.02 g), sodium acetate trihydrate (3.68 g), potassium chloride (0.37 g), magnesium chloride hexahydrate (0.30 g), water for injection (q.s. to 1000 mL).

[0317] Comparable cell growth was observed even after dilution of the iHPL medium composition with Plasma-Lyte 148.

[0318] Similar results are obtained with lysates from iPSC-derived platelets obtained by the alternative method according to Example 2.

[0319] Similar results are obtained with other MSCs types other than adipose tissue MSC (AT-MSC) or even non-stem cell types, but highest cell growth was overall seen for MSCs.P37368PC00 / MCR - 34 -

[0320] Example 4: protein and growth factor content determination

[0321] Methods

[0322] Aliquots of the stock cell culture supplements according to Example 2 (Table 1) were frozen and used for various protein and growth factor content determinations. Total protein content was determined with a Bicinchoninic acid (BCA) assay. The concentration of individual proteins was determined by enzyme-linked immunosorbent assay (ELISA).

[0323] Results.

[0324] Figure 4 shows the total protein content (g / dl) for different cell culture supplements as determined with the BCA assay. Figure 5 shows the relative albumin content normalized to the plasma condition (%) for different cell culture supplements as determined with ELISA.

[0325] The total protein and albumin concentration was highest in the plasma-containing conditions, indicating that plasma proteins are involved in promoting cell growth (since the cells do not appear to grow in “iHPL”, i.e. induced platelet lysate alone without plasma).

[0326] Table 3 shows the concentration of PDGF-AB, IGF-1, EGF, VEGF in the different cell culture supplements as determined with ELISA. Growth factor concentrations were lowest in the “Plasma” only condition, indicating that most of the growth factors are mainly

[0327] derived from platelets. PDGF and EGF showed higher concentrations in the “Donor-derived HPL” group compared to other conditions. In contrast, VEGF showed higher levels in the “iHPL” and “iHPL composition” conditions compared to “Donor-derived HPL”.

[0328] IGF-1 is generally considered as one of the key factors in donor-derived human platelet lysate, however IGF was only detected in the “Donor-derived HPL” group and appears not / hardly produced by iPSC-derived platelets.P37368PC00 / MCR - 35 -

[0329] Table 3: concentration of PDGF-AB, IGF-1, EGF, VEGF in the different cell culture supplements as determined with ELISA.

[0330] Plasma Donor-derived iHPL iHPL

[0331] HPL composition Growth factor

[0332] (ng / ml)

[0333] PDGF-AB 1,15 23,63 5,83 9,05

[0334] IGF-1 0,15 4,54 0,03 0,02

[0335] EGF 0,06 0,70 0,28 0,19

[0336] VEGF 0,05 0,16 0,44 0,31

[0337]

[0338] Table 4 shows an overview of protein and growth factors concentration in the iHPL composition stock and in the final medium (5% iHPL composition).

[0339] Table 4: overview of protein and growth factors concentration in the iHPL composition stock and in the final medium (5% iHPL composition).

[0340] In iHPL composition stock In final medium (5% iHPL lysate composition)

[0341] Total protein 47,2 mg / ml 2,4 mg / ml

[0342] PDGF-AB 9,1 ng / ml 455 pg / ml

[0343] IGF-1 <0.1 ng / ml <1 pg / ml

[0344] EGF 0,2 ng / ml 10 pg / ml

[0345] VEGF 0,3 ng / ml 15 pg / ml

[0346]

[0347] Other growth factors present in the iHPL composition are (calculated on final medium with 5% iHPL composition):

[0348] PDGF-AA (-100-1000 pg / ml), PDGF-BB (50-500 pg / ml), TGF-beta 1 (0.1-100 pg / ml), TGF- beta2 (0.1-100 pg / ml), BDNF (0.1-100 pg / ml), bFGF (0.1-100 pg / ml), GDF-15 (0.1-100 pg / ml), IGFBP-1 (0.1-100 pg / ml), IGFBP-2 (0.1-100 pg / ml), SCF-R (0.1-100 pg / ml), TIMP-1 (0.1-100 pg / ml).

[0349] Example 5: Effect of using alternative protein sources (e.g. albumin, serum) or further co-factors in combination with the induced platelet lysate on cell culture growth

[0350] Table 5 shows the effect of using alternative protein sources (e.g. albumin, human serum, serum replacement) or further co-factors in combination with the induced platelet lysate on cell culture growth. The cell culture experiment is performed according to Example 2.P37368PC00 / MCR - 36 -

[0351] Addition of serum or albumin to induced platelet lysate improves the cell growth. However, highest cell growth is seen for the combination of human plasma and induced platelet lysate, and therefore is most preferred. Serum replacement (e.g. CELLstart) leads to only low cell growth.

[0352] The addition of plasma to donor-derived HPL did not further enhance the cell growthpromoting effect, pointing towards a synergistic interaction between specifically induced platelet-derived and plasma-derived factors.

[0353] Heparin or heparin sulfate (i.e. “sulphate”) is found to provide for anticoagulation, but also further enhances the cell growth in combination with the induced platelet lysate. Dextran or dextran sulphate can be used as xeno-free alternative to heparin. However, it appears that use of heparin leads to highest cell growth and therefore is most preferred. Heparinoid polysaccharides appears not to have a further enhancing effect.

[0354] Use of NAD+ Boosters (e.g., NMN or Nicotinamide Riboside) appears beneficial in combination with induced platelet lysate (and plasma).

[0355] The addition of activating factors such as thrombin or platelet activating factor (PAF) to the induced platelets before lysis can further enhance the cell growth-promoting effect of the induced platelet lysate. This is particularly the case in combination with the use of diluent solutions (e.g. Plasma-Lyte) for the preparation of the iHPL composition and / or when using lower concentrations of induced platelets (lysate).

[0356] Overall, high cell growth is seen for induced platelet lysate in combination with human plasma, but which is even further improved by further adding anticoagulation / cell growth promoting factors (e.g. heparin, dextran) or NAD+boosters. In addition or alternatively, stimulating the induced platelets by adding platelet-activating factors before lysis is also beneficial for cell growth.P37368PC00 / MCR - 37 -

[0357] Table 5. The effect of using alternative protein sources (e.g. albumin, serum) or further cofactors in combination with platelet lysates on cell culture growth. Donor-derived HPL=donor-derived human platelet lysate. iHPL=induced human platelet lysate

[0358] Lysate condition Additional factor Stem cell growth Donor-derived HPL - ++

[0359] Donor-derived - ++

[0360] HPL+plasma

[0361] Donor-derived HPL Heparin ++

[0362] iHPL - iHPL+serum - - / +

[0363] iHPL+serum Heparin - / +

[0364] iHPL+albumin - - / +

[0365] iHPL+albumin Heparin - / +

[0366] iHPL+serum replacement - iHPL+serum replacement Heparin

[0367] iHPL+plasma - ++

[0368] iHPL+plasma Heparin +++++

[0369] iHPL+plasma Dextran +++

[0370] iHPL+plasma Heparinoid polysaccharides ++

[0371] iHPL+plasma Thrombin +++

[0372] iHPL+plasma Platelet activating factor +++

[0373] iHPL+plasma Nicotinamide Mononucleotide (NMN) +++

[0374] iHPL+plasma Nicotinamide Riboside +++

[0375]

[0376] Example 6: Effects of human plasma vs. human serum albumin in cell culture in combination with induced platelet lysate

[0377] Method

[0378] Induced human platelet lysate + human plasma (denoted herein as ““iHPL composition”) was prepared as described in Example 3. Donor-derived human platelet lysate (denoted herein as “Donor-derived HPL”, prepared as described in Example 3) and human serum albumin were included as further cell culture supplements.

[0379] The effect of the supplements (5% v / v add to the medium) was studied on adipose tissue-derived MSC cell culture according to the same cell culture protocol as described in Example 3. The cells were passaged every four days.P37368PC00 / MCR - 38 -

[0380] The normalized growth rate (p / day) relative to the donor-derived HPL group was determined as follows:

[0381] The specific growth rate (p) describes the exponential growth rate per day and is calculated using viable cell counts at the beginning and end of a passage period:

[0382] _ In(jVt)- In (Nt)

[0383]

[0384] Where:

[0385] • No= initial viable cell number (at seeding)

[0386] • Nt= viable cell number at harvest

[0387] • t = culture time in days

[0388] • In = natural logarithm

[0389] The unit of p is day-1. A higher p indicates faster cell proliferation under the respective culture condition.

[0390] The cell culture supplements as tested in present Example are as according to Table 6.

[0391] Table 6. Overview of cell culture supplements tested. hPU=human platelet units (= 3 x 1011platelets in 250 mL)

[0392] Supplement condition Preparation Final concentration in medium (% v / v)

[0393] “Donor-derived HPL” • 5% lysate (-0.05 hPU) Donor-derived human platelet

[0394] lysate (-1 hPU)

[0395] “iHPL composition” -700 pL platelet solution + • -0.6 % platelet lysate induced human platelet lysate 5075 pl fibrinogen-depleted (-0.05 hPU)

[0396] + human plasma plasma (~1 hPU) • -4.4% plasma

[0397] - lysis and centrifugation

[0398] - 0.4 pl / ml Heparin (stock

[0399] solution 5000 ll / rnl) added

[0400] (to 2 U / rnL)

[0401] “iHPL+ HSA” -620 pL platelet solution + • -0.6 % platelet lysate induced human platelet lysate 4495 pl HSA (stock (-0.05 hPU)

[0402] + human serum albumin solution 100 mg / mL) • -4.4% HSA solution - lysis and centrifugation

[0403]

[0404] P37368PC00 / MCR - 39 -

[0405] Results

[0406] Table 7 shows the growth rate of the cells cultured in medium supplemented with the “iHPL composition” or “iHPL+HSA” supplement at the 1st, 2nd or 3rd passage of culture, normalized to the growth rate of the donor-derived HPL.

[0407] In line with the results in Examples 3 and 4, the “iHPL composition” showed improved growth relative to the donor-derived HPL group, which became more apparent at increasing passage numbers.

[0408] In contrast, poor cell growth was seen in the ““iHPL+HSA” group, indicating that human serum albumin cannot replace human plasma as protein source in the combination with induced platelet lysate.

[0409] Table 7: Normalized growth rate (p / day) for the different cell culture supplements at the 1st, 2nd or 3rd passage of culture

[0410] Donor-derived iHPL iHPL+ HSA

[0411] HPL composition

[0412] Passage no.

[0413] First 1.00 1.10 0.11

[0414] Second 1.00 1.22 0.00

[0415] Third 1.00 1.71 0.00

[0416]

[0417] Example 7: comparison of growth factor and cytokine profile between donor-derived HPL and iHPL.

[0418] ELISA analysis was used to further measure different growth factors and cytokines in the donor-derived HPL and iHPL composition, which were prepared as described in Example 3.

[0419] A comparison was made with human plasma.P37368PC00 / MCR - 40 -

[0420] Table 8: concentration of PDGF-AB, EGF, VEGF, SCF, FGF-2, TGF-beta, IGF-1, IL-2 in the different cell culture supplements as determined with ELISA.

[0421] Growth Donor-derived HPL iHPL composition Plasma

[0422] factor

[0423] PDGF-AB 19.32 ng / ml 13.00 ng / ml 0.00 ng / ml

[0424] EGF 0.57 ng / ml 0.30 ng / ml 0.00 ng / ml

[0425] VEGF 0.71 ng / ml 1.14 ng / ml 0.09 ng / ml

[0426] SCF 0.40 ng / ml 0.48 ng / ml 0.35 ng / ml

[0427] FGF-2 0.07 ng / ml 0.09 ng / ml 0.00 ng / ml

[0428] TGF-beta 0.01 ng / ml 0.03 ng / ml 0.07 ng / ml

[0429] IGF-1 0.31 pg / ml 0.00 pg / ml 0.11 pg / ml

[0430] IL-2 0.06 ng / ml 0.00 ng / ml 0.01 ng / ml

[0431]

[0432] Overall, the results are in line with the Example 4 / Table 3.

[0433] Growth factor concentrations were lowest in the “Plasma” only condition, indicating that most of the growth factors are mainly derived from platelets.

[0434] As expected, IGF-1 is found in donor-derived human platelet lysate, but is not detected in the “iHPL composition”. Moreover, the “donor-derived HPL” contained IL-2, however this was not detected in the “iHPL composition”.

[0435] The differences in cytokine and growth factor profile between donor-derived and induced platelet lysates - in particular the selective presence of IGF-1 and IL-2 in donor-derived platelet lysate -allows the donor material to be distinguished from the in vitro induced material.

[0436] In particular, the donor-derived HPL has a signature reflecting residual plasma components or immune cell contributions, but which is absent in case of the more defined in vitro process of obtaining induced-HPL.

[0437] These results suggest that it is possible to identify further markers to distinguish induced platelet lysate from donor-derived platelet lysate, in addition to the markers IGF-1 and IL-2 already identified.

Claims

P37368PC00 / MCR - 41 -CLAIMS1. Method of producing an induced pluripotent stem cell (iPSC)-derived artificial platelet lysate composition suitable as cell culture supplement, the method comprising the steps of:a) providing iPSC-derived artificial platelets;b) lysing at least part of the iPSC-derived artificial platelets to provide an iPSC- derived artificial platelet lysate;c) combining the iPSC-derived artificial platelet lysate with human plasma in relative amounts such that- the iPSC-derived artificial platelet lysate provides platelet proteins in an amount of 0.01-5 mg / ml, calculated on the total of the iPSC-derived artificial platelet lysate and the human plasma; and- the amount of human plasma is 65-95% (v / v) and / or the human plasma provides plasma proteins in an amount of 5-200 mg / ml, calculated on the total of the iPSC- derived artificial platelet lysate and the human plasma.

2. Method according to claim 1, wherein in step c) the iPSC-derived artificial platelet lysate is combined with the human plasma in relative amounts such that the iPSC- derived artificial platelet lysate provides platelet proteins in an amount of 0.1-2 mg / ml, calculated on the total of the iPSC-derived artificial platelet lysate and the human plasma.

3. Method according to claim 1 or 2, wherein in step c) the iPSC-derived artificial platelet lysate is combined with the human plasma in relative amounts such that the human plasma provides plasma proteins in an amount of 10-100 mg / ml, calculated on the total of the iPSC-derived artificial platelet lysate and the human plasma.

4. Method according to any one of the previous claims, wherein the iPSC-derived artificial platelet lysate and human plasma are further combined with one or more anticoagulants selected from the group consisting of heparin, heparin sulfate and dextran.

5. Method according to any one of the previous claims, wherein the iPSC-derived artificial platelet lysate and human plasma are further combined with thrombinP37368PC00 / MCR - 42 -and / or platelet-activating factor (PAF).

6. Method of producing a medium composition suitable for cell culture, the method comprising the steps of:a) providing iPSC-derived artificial platelets;b) lysing at least part of the iPSC-derived artificial platelets to provide an iPSC- derived artificial platelet lysate;c) combining the iPSC-derived artificial platelet lysate with human plasma and basal medium to obtain the medium composition, in relative amounts such that - the amount of iPSC-derived artificial platelet lysate is 0.001-1 mg / ml, preferably 0.01-0.1 mg / ml, calculated on the medium composition;- the amount of human plasma is 1-20% (v / v), preferably 5-15% (v / v) and / or in an amount such that it provides plasma proteins in an amount of 0.5-50 mg / ml, preferably 1.0-10 mg / ml, calculated on the medium composition; and- the amount of basal medium is 75-97% (v / v), calculated on the medium composition.

7. Method according to claim 6, wherein the iPSC-derived artificial platelet lysate, human plasma and basal medium are further combined with one or more anticoagulants selected from the group consisting of heparin, heparin sulfate and dextran.

8. Method according to claim 6 or 7, wherein the iPSC-derived artificial platelet lysate, human plasma and basal medium are further combined with thrombin and / or PAF.

9. iPSC-derived artificial platelet lysate composition suitable as cell culture supplement, comprising- iPSC-derived artificial platelet lysate, providing platelet proteins in a total amount of 0.01-5 mg / ml, preferably 0.1-2 mg / ml, calculated on the iPSC-derived artificial platelet lysate composition; and- human plasma, wherein the amount of plasma is 65-95% (v / v) and / or in an amount such that it provides plasma proteins in an amount of 10-100 mg / ml, calculated on the iPSC-derived artificial platelet lysate composition.

10. iPSC-derived artificial platelet lysate composition according to claim 9, further comprising one or more anticoagulants selected from the group consisting ofP37368PC00 / MCR - 43 -heparin, heparin sulfate and dextran.

11. iPSC-derived artificial platelet lysate composition according to claim 9 or 10, further comprising thrombin and / or PAF.

12. Medium composition suitable for cell culture, the medium composition comprising - basal medium, in an amount of 75-97% (v / v), calculated on the medium composition,- human artificial platelet lysate providing platelet proteins in a total amount of 0.001-0.1 mg / ml, calculated on the medium composition, and- human plasma, wherein the amount of the plasma is 1-20% (v / v), preferably 5- 15% (v / v) and / or in an amount such that it provides plasma proteins in an amount of 0.5-50 mg / ml, preferably 1.0-10 mg / ml, calculated on the medium composition.

13. Medium composition according to claim 12, further comprising one or more anticoagulants selected from the group consisting of heparin, heparin sulfate and dextran.

14. Medium composition according to claim 13, further comprising thrombin and / or PAF.

15. Use of the iPSC-derived artificial platelet lysate composition according to any one of claims 9-11 or the medium composition according to any one of claims 12-14 in cell culture, a tissue-engineered product or an advanced therapy medicinal product (ATMP).

16. Use according to claim 15, wherein the use is in the culture of stem cells, preferably a mesenchymal stem cell (MSC), such as a bone marrow MSC (BM- MSC), an adipose tissue MSC (AT-MSC), a Wharton's Jelly MSC (WJ-MSC), an umbilical cord MSC (UC-MSC), a placenta MSC (PL-MSC) or a dental pulp MSC (DP-MSC).